Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
International Myeloma Society (IMS)
IMW 2019
IMW 2019
Daratumumab-Based Quad Regimen (D-RVd) Improves Depth of Response in Transplant-Eligible NDMM: GRIFFIN Study
IMW 2019
Researchers report promising findings for a novel quad regimen, D-RVd, compared with RVd in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem-cell transplant.
Read More ›
Real-World Outcomes of Triple-Class Refractory, Penta-Exposed RRMM
IMW 2019
A retrospective analysis suggests improved survival outcomes with selinexor plus dexamethasone compared with standard treatments in triple-class relapsed or refractory multiple myeloma (RRMM).
Read More ›
SC Daratumumab Combined with Standard MM Regimens: Open-Label, Multicenter, Phase 2 Study: PLEIADES
IMW 2019
New data suggest that combinations using a subcutaneous (SC) co-formulation of daratumumab with recombinant human hyaluronidase have similar clinical activity and safety as intravenous daratumumab in patients with newly diagnosed multiple myeloma (MM).
Read More ›
First-in-Human Study of AMG 420, an Anti-BCMA Bispecific T-Cell Engager (BiTEĀ®), for Relapsed or Refractory Multiple Myeloma
IMW 2019
This first-in-human study shows that AMG 420, a BiTE antibody that directs the immune system to target B-cell maturation antigen (BCMA) on the tumor cell and CD3 on T-cells, may be effective and safe.
Read More ›
Melflufen in RRMM with Extramedullary Disease: Phase 2 HORIZON Study
IMW 2019
Researchers report positive data for patients with relapsed or refractory multiple myeloma (RRMM) and extramedullary disease in the phase 2 HORIZON study of melflufen plus dexamethasone.
Read More ›
CT053, Anti-BCMA CAR T-Cell Therapy, for Relapsed or Refractory MM: Proof of Concept
IMW 2019
This phase 1 study demonstrates that CT053, a B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell product, is effective and safe in patients with multiply relapsed multiple myeloma (MM).
Read More ›
Safety of Rapid Daratumumab Infusion in RRMM
IMW 2019
This study reports successful administration of intravenous daratumumab over 90 minutes for patients with relapsed or refractory multiple myeloma (RRMM).
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us